Pleiotrophin produced by multiple myeloma induces transdifferentiation of monocytes into vascular endothelial cells: A novel mechanism of tumor-induced vasculogenesis

Blood

Volumn 113, Issue 9, 2009, Pages 1992-2002

  Chen, Haiming ^a   Campbell, Richard A ^a   Chang, Yunchao ^b   Li, Mingjie ^a   Wang, Cathy S ^a   Li, Jennifer ^a   Sanchez, Eric ^a   Share, Michael ^a   Steinberg, Jeffrey ^a   Berenson, Ariana ^a   Shalitin, Dror ^a   Zeng, Zhaohui ^c   Gui, Dorina ^d   Perez Pinera, Pablo ^b   Berenson, Ronald J ^e   Said, Jonathan ^d   Bonavida, Benjamin ^f   Deuel, Thomas F ^b   Berenson, James R ^a  

^a INSTITUTE FOR MYELOMA AND BONE CANCER RESEARCH   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c CEDARS SINAI MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e HemaQuest   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN RECEPTOR; CD133 ANTIGEN; CD14 ANTIGEN; COLONY STIMULATING FACTOR 1; GREEN FLUORESCENT PROTEIN; PLEIOTROPHIN; PLEIOTROPHIN ANTIBODY; PROTEIN ANTIBODY; UNCLASSIFIED DRUG; VASCULAR ENDOTHELIAL CADHERIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2; VON WILLEBRAND FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; BLOOD CELL; BLOOD VESSEL; BONE MARROW CULTURE; CELL TRANSDIFFERENTIATION; CONTROLLED STUDY; ENDOTHELIUM CELL; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; MONOCYTE; MOUSE; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCID MOUSE; SERUM; TUMOR VASCULARIZATION; VASCULAR ENDOTHELIUM;

EID: 61849115658     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-02-133751     Document Type: Article

References (67)

1. Bertolini F, Shaked Y, Mancuso P, Kerbel RS. The multifaceted circulating endothelial cell in cancer: towards marker and target identification. Nat Rev Cancer. 2006;6:835-845.
2. Isner JM, Asahara T. Angiogenesis and vasculogenesis as therapeutic strategies for postnatal neovascularization. J Clin Invest. 1999;103:1231-1236.
3. Shi Q, Rafii S, Wu MH, et al. Evidence for circulating bone marrow-derived endothelial cells. Blood. 1998;92:362-367.
4. Jiang S, Walker L, Afentoulis M, et al. Transplanted human bone marrow contributes to vascular endothelium. Proc Natl Acad Sci U S A. 2004;101:16891-16896.
5. Zhang H, Vakil V, Braunstein M, et al. Circulating endothelial progenitor cells in multiple myeloma: implications and significance. Blood. 2005;105: 3286-3294.
6. Gao D, Nolan DJ, Mellick AS, Bambino K, McDonnell K, Mittal V. Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis. Science. 2008;319:195-198.
7. Rehman J, Li J, Orschell CM, March KL. Peripheral blood "endothelial progenitor cells" are derived from monocyte/macrophages and secrete angiogenic growth factors. Circulation. 2003;107:1164-1169.
8. Bailey AS, Willenbring H, Jiang S, et al. Myeloid lineage progenitors give rise to vascular endothelium. Proc Natl Acad Sci U SA. 2006;103:13156- 13161.
9. Conejo-Garcia JR, Benencia F, Courreges MC, et al. Tumor-infiltrating dendritic cell precursors recruited by a beta-defensin contribute to vasculogenesis under the influence of Vegf-A. Nat Med. 2004;10:950-958.
10. Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell. 2006;124:263-266.
11. Stearman RS, Dwyer-Nield L, Grady MC, Malkinson AM, Geraci MW. Amacrophage gene expression signature defines a field effect in the lung tumor microenvironment. Cancer Res. 2008; 68:34-43.
12. Yeh HJ, He YY, Xu J, Hsu CY, Deuel TF. Upregulation of pleiotrophin gene expression in developing microvasculature, macrophages, and astrocytes after acute ischemic brain injury. J Neurosci. 1998;18:3699-3707.
13. Christman KL, Fang Q, Kim AJ, et al. Pleiotrophin induces formation of functional neovasculature in vivo. Biochem Biophys Res Commun. 2005;332:1146-1152.
14. Silos-Santiago I, Yeh HJ, Gurrieri MA, et al. Localization of pleiotrophin and its mRNA in subpopulations of neurons and their corresponding axonal tracts suggests important roles in neuralglial interactions during development and in maturity. J Neurobiol. 1996;31:283-296.
15. Li YS, Milner PG, Chauhan AK, et al. Cloning and expression of a developmentally regulated protein that induces mitogenic and neurite outgrowth activity. Science. 1990;250:1690-1694.
16. Zhang N, Deuel TF. Pleiotrophin and midkine, a family of mitogenic and angiogenic heparin-binding growth and differentiation factors. Curr Opin Hematol. 1999;6:44-650.
17. Chang Y, Zuka M, Perez-Pinera P, et al. Secretion of pleiotrophin stimulates breast cancer progression through remodeling of the tumor microenvironment. Proc Natl Acad Sci U S A. 2007;104:10888-10893.
18. Nakagawara A, Milbrandt J, Muramatsu T, et al. Differential expression of pleiotrophin and midkine in advanced neuroblastomas. Cancer Res. 1995;55:1792-1797.
19. Zhang N, Zhong R, Wang ZY, Deuel TF. Human breast cancer growth inhibited in vivo by a dominant negative pleiotrophin mutant. J Biol Chem. 1997;272:16733-16736.
20. Zhang N, Zhong R, Perez-Pinera P, et al. Identification of the angiogenesis signaling domain in pleiotrophin defines a mechanism of the angiogenic switch. Biochem Biophys Res Commun. 2006;343:653-658.
21. Chen H, Gordon MS, Campbell RA, et al. Pleiotrophin is highly expressed by myeloma cells and promotes myeloma tumor growth. Blood. 2007;110:287-295.
22. Yeh HS, Chen H, Manyak SJ, et al. Serum pleiotrophin levels are elevated in multiple myeloma patients and correlate with disease status. Br J Haematol. 2006;133:526-529.
23. Jäger R, List B, Knabbe C, et al. Serum levels of the angiogenic factor pleiotrophin in relation to disease stage in lung cancer patients. Br J Cancer. 2002;86:858-863.
24. Souttou B, Juhl H, Hackenbruck J, et al. Relationship between serum concentrations of the growth factor pleiotrophin and pleiotrophin-positive tumors. J Natl Cancer Inst. 1998;90:1468-1473.
25. Malerczyk C, Schulte AM, Czubayko F, et al. Ribozyme targeting of the growth factor pleiotrophin in established tumors: a gene therapy approach. Gene Ther. 2005;12:339-346.
26. Grzelinski M, Urban-Klein B, Martens T, et al. RNA interference-mediated gene silencing of pleiotrophin through polyethylenimine-complexed small interfering RNAs in vivo exerts antitumoral effects in glioblastoma xenografts. Hum Gene Ther. 2006;17:751-766.
27. Folkman J. Angiogenesis. Annu Rev Med. 2006;57:1-18.
28. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9:669-676.
29. Podar K, Anderson KC. Inhibition of VEGF signaling pathways in multiple myeloma and other malignancies. Cell Cycle. 2007;6:538-542.
30. Campbell RA, Sanchez E, Chen H, et al. Anti-VEGF antibody treatment markedly inhibits tumor growth in SCID-hu models of human multiple myeloma [abstract]. Blood. 2006;108:846a.
31. Akagawa KS, Kamoshita K, Tokunaga T. Effects of granulocyte-macrophage colony-stimulating factor and colony-stimulating factor-1 on the proliferation and differentiation of murine alveolar macrophages. J Immunol. 1988;141:3383-3390.
32. Yano S, Nishioka Y, Nokihara H, Sone S. Macrophage colony-stimulating factor gene transduction into human lung cancer cells differentially regulates metastasis formations in various organ microenvironments of natural killer cell-depleted SCID mice. Cancer Res. 1997;57:784-790.
33. Frangogiannis NG, Mendoza LH, Ren G, et al. MCSF expression is induced in healing myocardial infarcts and may regulate monocyte and endothelial cell phenotype. Am J Physiol Heart Circ Physiol. 2003;285:H483-H492.
34. Okazaki T, Ebihara S, Takahashi H,Asada M, Kanda A, Sasaki H. Macrophage colony-stimulating factor induces vascular endothelial growth factor production in skeletal muscle and promotes tumor angiogenesis. J Immunol. 2005;174:7531-7538.
35. Wurmser AE, Nakashima K, Summers RG, et al. Cell fusion-independent differentiation of neural stem cells to the endothelial lineage. Nature. 2004;430:350-356.
36. Yoon J, Shim WJ, Ro YM, Lim DS. Transdifferentiation of mesenchymal stem cells into cardiomyocytes by direct cell-to-cell contact with neonatal cardiomyocyte but not adult cardiomyocytes. Ann Hematol. 2005;84:715-721.
37. + monocytes. Immunol Cell Biol. 2006;84:209-217.
38. Blondet B, Carpentier G, Lafdil F, Courty J. Pleiotrophin cellular localization in nerve regeneration after peripheral nerve injury. J Histochem Cytochem. 2005;53:971-977.
39. Kalamasz D, Long SA, Taniguchi R, Buckner JH, Berenson RJ, Bonyhadi M. Optimization of human T-cell expansion ex vivo using magnetic beads conjugated with anti-CD3 and Anti-CD28 antibodies. J Immunother. 2004;27:405-418.
40. Campbell RA, Manyak SJ, Yang HH, et al. LAG-lambda-1: a clinically relevant drug resistant human multiple myeloma tumor murine model that enables rapid evaluation of treatments for multiple myeloma. Int J Oncol. 2006;28:1409-1417.
41. Emmert-Buck MR, Bonner RF, Smith PD, et al. Laser capture microdissection. Science. 1996;274:998-1001.
42. Simone NL, Bonner RF, Gillespie JW, Emmert-Buck MR, Liotta LA. Laser-capture microdissection: opening the microscopic frontier to molecular analysis. Trends Genet. 1998;14:272-276.
43. Nelson DL, Ledbetter SA, Corbo L, et al. Alu polymerase chain reaction: a method for rapid isolation of human-specific sequences from complex DNA sources. Proc Natl Acad Sci USA. 1989;86:6686-6690.
44. Gronthos S, Brahim J, Li W, et al. Stem cell properties of human dental pulp stem cells. J Dent Res. 2002;81:531-535.
45. Miura M, Gronthos S, Zhao M, et al. SHED: stem cells from human exfoliated deciduous teeth. Proc Natl Acad Sci USA. 2003;100:5807-5812.
46. Venneri MA, De Palma M, Ponzoni M, et al. Identification of proangiogenic TIE2-expressing monocytes (TEMs) in human peripheral blood and cancer. Blood. 2007;109:5276-5285.
47. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-2342.
48. Miller K, Wang M, Gralow J, et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med. 2007;357:2666-2676.
49. Dudek AZ, Bodempudi V, Welsh BW, et al. Systemic inhibition of tumour angiogenesis by endothelial cell-based gene therapy. Br J Cancer. 2007;97:513-522.
50. Sharifi BG, Zeng Z, Wang L, et al. Pleiotrophin induces transdifferentiation of monocytes into functional endothelial cells. Arterioscler Thromb Vasc Biol. 2006;26:1273-1280.
51. Peters BA, Diaz LA, Polyak K, et al. Contribution of bone marrow-derived endothelial cells to human tumor vasculature. Nat Med. 2005;11:261-262.
52. Guo K, Li J, Wang H, et al. PRL-3 initiates tumor angiogenesis by recruiting endothelial cells in vitro and in vivo. Cancer Res. 2006;66:9625-9635.
53. Rigolin GM, Fraulini C, Ciccone M, et al. Neoplastic circulating endothelial cells in multiple myeloma with 13q14 deletion. Blood. 2006;107:2531-2535.
54. Loureiro RM, D'Amore PA. Transcriptional regulation of vascular endothelial growth factor in cancer. Cytokine Growth Factor Rev. 2005;16:77-89.
55. Benjamin LE, Golijanin D, Itin A, Pode D, Keshet E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest. 1999;103:159-165.
56. Sapi E. The role of CSF-1 in normal physiology of mammary gland and breast cancer: an update. Exp Biol Med (Maywood). 2004;229:1-11.
57. Lin EY, Nguyen AV, Russell RG, Pollard JW. Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med. 2001;193:727-740.
58. Eubank TD, Galloway M, Montague CM, Waldman WJ, Marsh CB. M-CSF induces vascular endothelial growth factor production and angiogenic activity from human monocytes. J Immunol. 2003;171:2637-2643.
59. Magnusson PU, Dimberg A, Mellberg S, Lukinius A, Claesson-Welsh L. FGFR-1 regulates angiogenesis through cytokines interleukin-4 and pleiotrophin. Blood. 2007;110:4214-4222.
60. Choudhuri R, Zhang HT, Donnini S, Ziche M, Bicknell R. An angiogenic role for the neurokines midkine and pleiotrophin in tumorigenesis. Cancer Res. 1997;57:1814-1819.
61. Perez-Pinera P, Chang Y, Deuel TF. Pleiotrophin, a multifunctional tumor promoter through induction of tumor angiogenesis, remodeling of the tumor microenvironment, and activation of stromal fibroblasts. Cell Cycle. 2007;6:2877-2883.
62. Li G, Hu Y, Huo Y, et al. PTEN deletion leads to up-regulation of a secreted growth factor pleiotrophin. J Biol Chem. 2006;281:10663-10668.
63. Minehata K, Mukouyama YS, Sekiguchi T, Hara T, Miyajima A. Macrophage colony stimulating factor modulates the development of hematopoiesis by stimulating the differentiation of endothelial cells in the AGM region. Blood. 2002;99:2360-2368.
64. Ng YS, Krilleke D, Shima DT. VEGF function in vascular pathogenesis. Exp Cell Res. 2006;312:527-537.
65. Usui T, Yamagami S, Yokoo S, Mimura T, Ono K, Amano S. Gene expression profile in corneal neovascularization identified by immunology related macroarray. Mol Vis. 2004;10:832-836.
66. Hristov M, Erl W, Weber PC. Endothelial progenitor cells: isolation and characterization. Trends Cardiovasc Med. 2003;13:201-206.
67. Leong AS-Y, Cooper K. Manual of diagnostic antibodies for immunohistology. Cambridge, United Kingdom: Greenwich Medical Media; 2003.